Seeking Alpha

Taro Pharmaceutical Industries (TARO), a maker of generic drugs, has all the hallmarks of a beautifully underfollowed gem: a boring business, a horrible website, coverage by a single analyst, few Seeking Alpha followers, a blizzard of irrelevant SEC filings hiding the useful documents, and zero self-promotion. Want flashy presentations telling you in a few pithy slides exactly how the business functions? Don't expect it from Taro. Nevertheless, despite appreciating dramatically since the prescient articles found here and here by Retail Investor, Taro has a wonderful business with good long-term growth prospects. For serious investors who believe that making money is more important than having conversation-starters available for cocktail parties, Taro is a reasonable and conservative investment...

Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: